Du Junxia, Zhao Xiaolin, Ding Xiaonan, Han Qiuxia, Duan Yingjie, Ren Qinqin, Wang Haoran, Song Chenwen, Wang Xiaochen, Zhang Dong, Zhu Hanyu
Department of Nephrology, First Medical Center of Chinese People's Liberation Army General Hospital, Nephrology Institute of the Chinese People's Liberation Army, National Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing 100853, China.
Medical School of Chinese People's Liberation Army, Beijing 100853, China.
Microorganisms. 2024 Sep 12;12(9):1878. doi: 10.3390/microorganisms12091878.
The composition of the gut microbiota varies among end-stage renal disease (ESRD) patients on the basis of their mode of renal replacement therapy (RRT), with notably more pronounced dysbiosis occurring in those undergoing hemodialysis (HD). Interventions such as dialysis catheters, unstable hemodynamics, strict dietary restrictions, and pharmacotherapy significantly alter the intestinal microenvironment, thus disrupting the gut microbiota composition in HD patients. The gut microbiota may influence HD-related complications, including cardiovascular disease (CVD), infections, anemia, and malnutrition, through mechanisms such as bacterial translocation, immune regulation, and the production of gut microbial metabolites, thereby affecting both the quality of life and the prognosis of patients. This review focuses on alterations in the gut microbiota and its metabolites in HD patients. Additionally, understanding the impact of the gut microbiota on the complications of HD could provide insights into the development of novel treatment strategies to prevent or alleviate complications in HD patients.
终末期肾病(ESRD)患者的肠道微生物群组成因其肾脏替代治疗(RRT)方式而异,在接受血液透析(HD)的患者中,菌群失调更为明显。诸如透析导管、不稳定的血流动力学、严格的饮食限制和药物治疗等干预措施会显著改变肠道微环境,从而破坏HD患者的肠道微生物群组成。肠道微生物群可能通过细菌易位、免疫调节和肠道微生物代谢产物的产生等机制影响与HD相关的并发症,包括心血管疾病(CVD)、感染、贫血和营养不良,进而影响患者的生活质量和预后。本综述重点关注HD患者肠道微生物群及其代谢产物的变化。此外,了解肠道微生物群对HD并发症的影响可为开发预防或减轻HD患者并发症的新治疗策略提供思路。